Clinical Trial Details
Braintumor Website

[Information provided by: ClinicalTrials.gov, which provides patients, family members, and members of the public easy and free access to information on clinical studies for a wide range of diseases and conditions.]

NCT01926171 : Icotinib With Whole Brain Radiation Therapy in NSCLC Patients With Brain Metastases
PhasePhase 4
AgesMin: 18 Years Max: 75 Years
Eligibility
Inclusion Criteria:

- Histological or cytological confirmation of non-small-cell lung cancer (NSCLC).

- Diagnosis of non-systematic brain metastases on a Gadolinium-enhanced MRI. More than
2 sites of intracranial metastases, or the longest diameter of the intracranial
lesion is more than 3cm.

- No other metastases except for brain metastases.

Exclusion Criteria:

- Previous usage of EGFR-TKI or antibody to EGFR: gefitinib, erlotinib, herceptin,
erbitux.

- CSF or MRI findings consistent with metastases of spinal cord, meninges or meningeal.
LinksPermanent Link to THIS page: https://virtualtrials.com/nct/display1trial.cfm?nct=NCT01926171      |      Link to official Clinicaltrials.gov listing
Locations



Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2019 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740